- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02312869
Local Assessment of Management of Burn Patients (LAMiNAR)
Local Assessment of Management of Burn Patients (LAMiNAR) - a Prospective Observational International Multicenter Cohort Study
In the general intensive care unit (ICU) population, there is strong evidence for benefit from lung-protective mechanical ventilation, including the use of low tidal volumes and adequate levels of positive end-expiratory pressure (PEEP). In burn patients it is highly uncertain whether these settings are beneficial and there are even concerns over safety of, in particular use of low tidal volumes. There is lack of international guidelines and consequently ventilation practice in burn patients may widely vary.
The primary objective is to determine ventilation practice in burn ICUs worldwide, focusing on the size of tidal volumes and the levels of PEEP used for burn patients. In addition, data on other strategies considered important in patients who receive ventilation are also collected, including data on neuromuscular blocking agents, sedatives and analgesics, and type and amount of intravenous fluids used in the period of ventilation. The secondary objective is to determine the association between tidal volume size and levels of PEEP, and duration of ventilation in burn patients.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Patient population: Consecutive burn patients admitted to participating burn ICUs who receive invasive ventilation, irrespective of severity of burn injury and/or presence of inhalation trauma are eligible for participation.
Data collection: includes burn patients admitted within a period of three months. Demographic and baseline data are collected from the clinical files on the day of admission. If available, standard of care and clinical outcome parameters are collected daily until day 14, death or discharge from ICU, whatever comes first.
Sample size: The primary objective is to determine (variations in) ventilation practice in burn patients in burn ICUs. Therefore, the sample size is based on the main secondary objective, which is to determine the association between the following ventilator settings: tidal volume, PEEP, FiO2 and mode; and outcome of burn patients. The investigators calculated the sample size for a multiple regression model: a sample size of at least 300 patients is required to have a power of 0.80, a significance level of 0.05, using an estimated effect size of 0.04, while using 4 independent variables in the model.
Ethics Approval: National coordinators will be responsible for clarifying the need for ethics approval and applying for this where appropriate according to local policy. Centres will not be permitted to record data unless ethics approval or an equivalent waiver is in place. The investigators expect that in most, if not every participating country, a patient informed consent is not be required.
Monitoring: Due to the observational nature of the study, a DSMB is not necessary.
Organization: National co-ordinators will lead the project within individual nations and identify participating hospitals, translate study paperwork, distribute study paperwork and ensure necessary regulatory approvals are in place. They provide assistance to the participating clinical sites in trial management, record keeping and data management. Local coordinators in each site will supervise data collection and ensure adherence to Good Clinical Practice during the trial.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
Zuid Holland
-
Amsterdam, Zuid Holland, Olanda, 1105AZ
- Academic Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Burns
- Admission to a participating burn ICU Need for invasive ventilation
- Informed consent (only if applicable in the country where data are collected)
Exclusion Criteria:
- None
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Ventilation parameters
Lasso di tempo: Up to 14 days during mechanical ventilation
|
Tidal volume size; milliliters per kilogram of predicted body weight
|
Up to 14 days during mechanical ventilation
|
Ventilation parameters
Lasso di tempo: Up to 14 days during mechanical ventilation
|
Level of positive end-expiratory pressure (PEEP); cm H2O
|
Up to 14 days during mechanical ventilation
|
Ventilation parameters
Lasso di tempo: Up to 14 days during mechanical ventilation
|
Fraction of oxygen in inspired air (FiO2), %
|
Up to 14 days during mechanical ventilation
|
Ventilation parameters
Lasso di tempo: Up to 14 days during mechanical ventilation
|
Mode of ventilation; assist-control or spontaneous modes of ventilation
|
Up to 14 days during mechanical ventilation
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Durata del soggiorno in terapia intensiva il giorno 90
Lasso di tempo: Fino al giorno 90
|
Tempo tra il ricovero e la dimissione o il decesso
|
Fino al giorno 90
|
Durata della degenza in ospedale il giorno 90
Lasso di tempo: Fino al giorno 90
|
Tempo tra il ricovero e la dimissione o il decesso
|
Fino al giorno 90
|
Mortalità per tutte le cause in terapia intensiva
Lasso di tempo: Fino al giorno 90
|
Qualsiasi decesso durante la degenza in terapia intensiva
|
Fino al giorno 90
|
Mortalità ospedaliera per tutte le cause
Lasso di tempo: Fino al giorno 90
|
Qualsiasi decesso durante la degenza in ospedale
|
Fino al giorno 90
|
Number of ventilator-free days and alive at day 28
Lasso di tempo: From day 1 to day 28
|
Defined as the number of days, from day 1 to day 28, the patient is alive and breathes without assistance of a mechanical ventilator, if the period of unassisted breathing lasted at least 24 consecutive hours.
Notably, if after successful withdrawal of mechanical ventilation the patient requires ventilation for a surgical procedure, this will not count as a 'ventilator day'.
If ventilation is prolonged after surgery due to respiratory insufficiency, the day(s) ventilation is required counts as a 'ventilator day'
|
From day 1 to day 28
|
Other Ventilation Parameters
Lasso di tempo: Up to 14 days during mechanical ventilation
|
Peak and plateau pressures or maximum airway pressure
|
Up to 14 days during mechanical ventilation
|
Other Ventilation Parameters
Lasso di tempo: Up to 14 days during mechanical ventilation
|
Respiratory rate
|
Up to 14 days during mechanical ventilation
|
Other Ventilation Parameters
Lasso di tempo: Up to 14 days during mechanical ventilation
|
Inspiration to expiration ratio
|
Up to 14 days during mechanical ventilation
|
Other Ventilation Parameters
Lasso di tempo: Up to 14 days during mechanical ventilation
|
Peripheral oxygen saturation
|
Up to 14 days during mechanical ventilation
|
Other Ventilation Parameters
Lasso di tempo: Up to 14 days during mechanical ventilation
|
Arterial blood gas parameters
|
Up to 14 days during mechanical ventilation
|
Need for Tracheostomy
Lasso di tempo: daily up to 14 days from inclusion
|
Need for tracheostomy, first tracheostomy will be assessed up to 14 days from inclusion
|
daily up to 14 days from inclusion
|
Daily Lung Injury Scores
Lasso di tempo: Up to 14 days during mechanical ventilation
|
Score based on chest X-ray findings (if obtained), PaO2/FiO2, PEEP level and respiratory compliance.
|
Up to 14 days during mechanical ventilation
|
Daily Sequential Organ Failure Assessment (SOFA)-scores
Lasso di tempo: Daily up to 14 days from inclusion
|
six-organ dysfunction/failure score measuring multiple organ failure daily
|
Daily up to 14 days from inclusion
|
Complications
Lasso di tempo: Daily up to 14 days from inclusion
|
Complications will include: Skin and soft tissue infections
|
Daily up to 14 days from inclusion
|
Complications
Lasso di tempo: Daily up to 14 days from inclusion
|
Complications will include: (Ventilator associated) Pneumonia
|
Daily up to 14 days from inclusion
|
Complications
Lasso di tempo: Daily up to 14 days from inclusion
|
Complications will include: Sepsis
|
Daily up to 14 days from inclusion
|
Complications
Lasso di tempo: Daily up to 14 days from inclusion
|
Complications will include: Acute respiratory distress syndrome according to Berlin criteria
|
Daily up to 14 days from inclusion
|
Complications
Lasso di tempo: Daily up to 14 days from inclusion
|
Complications will include: Acute renal failure
|
Daily up to 14 days from inclusion
|
Complications
Lasso di tempo: Daily up to 14 days from inclusion
|
Complications will include: Abdominal compartment syndrome
|
Daily up to 14 days from inclusion
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Standard care strategies
Lasso di tempo: Daily up to 14 days from inclusion
|
Strategies considered to be important in patients who receive ventilation, including: Fluid balance, types and dose of fluids used
|
Daily up to 14 days from inclusion
|
Standard care strategies
Lasso di tempo: Daily up to 14 days from inclusion
|
Strategies considered to be important in patients who receive ventilation, including: use of sedative and analgesic drugs
|
Daily up to 14 days from inclusion
|
Standard care strategies
Lasso di tempo: Daily up to 14 days from inclusion
|
Strategies considered to be important in patients who receive ventilation, including: use of sedation and delirium scores
|
Daily up to 14 days from inclusion
|
Standard care strategies
Lasso di tempo: Daily up to 14 days from inclusion
|
Strategies considered to be important in patients who receive ventilation, including: use of neuromuscular blocking agents
|
Daily up to 14 days from inclusion
|
Standard care strategies
Lasso di tempo: Daily up to 14 days from inclusion
|
Strategies considered to be important in patients who receive ventilation, including: use of antibiotic prophylaxis
|
Daily up to 14 days from inclusion
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Marcus J. Schultz, MD, PhD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- LAMiNAR
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su No intervention
-
RadiancyCompletatoLombalgia cronica da lieve a moderataIsraele
-
Sarah MorrowLawson Health Research InstituteCompletato
-
University of TulsaTerminatoSuicidio, tentatoStati Uniti
-
University of PittsburghReclutamentoDistrofia muscolare di DuchenneStati Uniti
-
Indiana UniversityUniversity of South Florida; National Institute on Minority Health and Health... e altri collaboratoriCompletatoIntervento DECIDE modificato | Trattamento come consueto gruppo di curaStati Uniti
-
Lisbon Institute of Global Mental Health - LIGMHColumbia UniversityReclutamentoDisturbi psicotici | Schizofrenia | Disordine bipolare | Disturbo affettivo schizoidePortogallo
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completato
-
University of MichiganNational Institute on Drug Abuse (NIDA)ReclutamentoUso di cannabisStati Uniti
-
Icahn School of Medicine at Mount SinaiReclutamento
-
Munich Municipal HospitalTechnical University of Munich; University of RegensburgSconosciuto